Background {#S0001}
==========

*Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kp*) are the leading causes of bloodstream infections (BSIs) involving gram-negative bacteria, and β-lactams are among the most used drugs for treatment of such infections. Globally, increasing attention is being focused on the growing involvement of extended-spectrum-β-lactamase (ESBL)-producing isolates of *Ec* and *Kp* in serious BSIs.[@CIT0001],[@CIT0002] This trend is due largely to the emergence of CTX-M ESBLs, a rapidly expanding group of enzymes that are being encountered with increasing frequency in both bacterial species.[@CIT0003],[@CIT0004] Carbapenems represent one therapeutic option for infections caused by multidrug-resistant (MDR) ESBL-producing organisms; however, resistance to this class of antibiotics has increased during the last decade.[@CIT0005] Carbapenem-resistant *Enterobacteriaceae*, particularly *Kp* producing *bla*~KPC~, are now responsible for a new dramatic scenario and are emerging as a relevant cause of health care-associated BSIs in several countries, including Italy.[@CIT0006]--[@CIT0008]

Detecting rapidly and accurately BSI pathogens is a critical factor for earlier implementation of effective treatment of these life-threatening infections. Although blood culture (BC) remains the gold standard for diagnosing BSIs, the time-consuming process of isolate identification/characterization with conventional culture-based methods has been improved by the development of faster technologies, allowing identification of the infecting pathogen directly from BC bottles.[@CIT0009] In addition to matrix-assisted laser desorption ionization--time of flight mass spectrometry (eg, MALDI BioTyper^TM^ system \[Bruker Daltonics, Bremen, Germany\]), various commercial BC-based nucleic acid assays can shorten the identification time of pathogens and/or resistance genes,[@CIT0010] and have added value for antibiotic stewardship decisions by decreasing the time to initiating appropriate antibiotic therapy.[@CIT0011]--[@CIT0015]

To provide rapid pathogens' characterization for early appropriate treatment of patients with *Ec*- or *Kp*-BSI hospitalized in a CTX-M and KPC-endemic setting, we implemented the laboratory's BC workflow that uses the eazyplex^®^ SuperBug CRE assay (Amplex Diagnostics GmbH, Biolife italiana SRL, Milan, Italy) when *Ec* or *Kp* organisms were identified by direct MALDI BioTyper^TM^ analysis from positive BCs.[@CIT0010] Clinical experience to date shows that this panel identifies the CTX-M-1--group and CTX-M-9--group ESBLs and the VIM (−1 to −37), NDM (−1 to −7), KPC (−2 to −15), and OXA-48-like (−48, −162, −204, and −244) carbapenemases with high accuracy when applied directly to both cultured bacterial and urine samples.[@CIT0016]--[@CIT0018] Our workflow was integrated with real-time result notification and inpatient infectious disease consultation team (IDCT) intervention. In the present one-year retrospective study, we assessed whether this laboratory/clinical workflow may have affected the timely prescription of appropriate antimicrobial therapy for BSIs caused by CTX-M ESBL- and/or carbapenemase-producing *Ec* or *Kp* organisms.

Methods {#S0002}
=======

This study was conducted from 15 January 2015 through 15 January 2016 at a 1,200-bed university hospital (Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy), under approval by our institutional Ethics Committee (no. 0040288/16). A central microbiology laboratory, which is open from 7:00 a.m. to 7:00 p.m., Monday through Friday and from 7:00 a.m. to 4:00 p.m., Saturday serves all the hospital wards. The hospital has an IDCT comprising four ID specialists, who operate on a request basis (via the hospital's computerized information system) by the physicians operating in medical and surgical wards (except for hematology unit and ICU, which have dedicated ID specialists). The IDCT takes charge of patients at the bedside within 24 hrs of the request.[@CIT0019] Eligible patients were adults (≥18 years old) with a first, clinically significant episode of BC-documented BSI for *Ec* or *Kp*. Patients were excluded if they died or were discharged before BC results were available, or if they had incomplete data.

[Figure 1](#F0001){ref-type="fig"} depicts the diagnostic workflow used in this study. When patients' BC signaled positive in either BACT/ALERT^®^ VIRTUO^TM^ (bioMérieux, Marcy l'Étoile, France) or BACTEC^TM^ FX (Becton Dickinson, Sparks, MD, USA) automated systems, aliquots from BC bottle broths were subjected to the direct MALDI BioTyper^TM^ analysis[@CIT0010] and, when *Ec* or *Kp* organisms were identified, the eazyplex^®^ SuperBug CRE assay was performed. MALDI BioTyper^TM^ identifications of *Ec* or *Kp* organisms were always concordant with those of reference (culture-based) identification methods ([Figure 1](#F0001){ref-type="fig"}). As described elsewhere,[@CIT0017] the eazyplex^®^ SuperBug CRE assay relies on a loop-mediated isothermal amplification (that covers the aforementioned carbapenemase variants) and a subsequent real-time fluorescence based visualization of the amplification products. For each patient, results of the laboratory procedure were immediately available to the IDCT. The microbiologist also informed the in-charge ID specialist about that identified organisms could harbor *bla* genes other than those detected in the eazyplex^®^ SuperBug CRE assay (eg, TEM/SHV ESBLs, plasmidic AmpC β-lactamases), which confer non-susceptibility to extended-spectrum cephalosporins (ESC) or carbapenems (carba). Antimicrobial minimum inhibitory concentrations (MICs) of the *Ec* or *Kp* isolates identified by the MALDI BioTyper^TM^ analysis were determined by antimicrobial susceptibility testing (AST) broth microdilution methods and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (version 8.0, <http://www.eucast.org/clinical_breakpoints/>). We performed phenotypic detection of resistance mechanisms according to the EUCAST guidelines (version 2.0, <http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/>). To confirm antimicrobial resistance profiles, all the *Ec* and *Kp* isolates underwent PCR sequencing of the *bla*~TEM~, *bla*~SHV~, *bla*~CTX-M~, *bla*~KPC~, *bla*~NDM~, *bla*~OXA-48-like~, *bla*~VIM~, and *bla*~AmpC~ genes.[@CIT0002],[@CIT0020]--[@CIT0022]Figure 1Diagnostic workflow using MALDI BioTyper^TM^ analysis/eazyplex^®^ SuperBug CRE assay (direct procedure) or culture-based methods (reference procedure) on positive blood cultures from *E. coli* or *K. pneumoniae* bloodstream infections (BSIs). Results from both the diagnostic procedures were notified to an IDCT for streamlining the antimicrobial treatments of BSIs.**Abbreviations:** ID, identification; IDCT, infectious disease consultation team.

Diagnostic and clinical definitions {#S0003-S2001}
-----------------------------------

Time to detection of growth (TTD) was the time from when the BC bottle entered into the BC system to when it signaled positive. The time to result (TTR) was the time elapsed between the BC system entry and completion of the aforementioned direct-detection procedure. We assessed the appropriateness of antibiotic treatments at the time of BC collection (empirical therapy) and after notification of the procedure (targeted therapy) or AST (definitive therapy) results. We defined the antimicrobial treatment as appropriate when the patient received the first (empirical) and/or subsequent (diagnostic-driven) antibiotic with known susceptibility by microbiology report.

Results {#S0003}
=======

We studied 321 patients with *Ec* (n=214) or *Kp* (n=107) BSIs. The mean TTD for the patient-unique positive BCs (n=321) was 10.3 h (range: 2--90 h). The mean TTR for the 151 (47.0%) *Ec* or *Kp* organisms harboring *bla*~CTX-M~ and/or *bla*~KPC~ and/or *bla*~VIM~ (as detected by the MALDI BioTyper^TM^ analysis and eazyplex^®^ SuperBug CRE assay) was 18.5 h (range: 3.3--96 h). The mean AST was 51 h (range: 36--141 h) for all the 321 *Ec* and *Kp* isolates, including 106 (33.0%) isolates that were non-susceptible to ESC but susceptible to carba (ESCR-carbaS phenotype) ([Table 1](#T0001){ref-type="table"}). Accordingly, ESBL production was detected in 36.0% (77/214) of the *Ec* isolates and in 21.5% (23/107) of the *Kp* isolates, and all the 100 isolates carried CTX-M ESBL genes. The *bla*~CMY-2~ gene (not detectable by the eazyplex^®^ SuperBug CRE assay) was detected in the remaining 1.8% (6/321) of *Ec* or *Kp* isolates. The proportions of the *Ec* or *Kp* isolates harboring carbapenemase genes (ESCR-carbaR phenotype) were 0.9% (2/214) and 45.8% (49/107), respectively, with *bla*~KPC-3~ being the most commonly detected gene ([Table 1](#T0001){ref-type="table"}).Table 1Antimicrobial susceptibilities for 321 *Escherichia coli* and *Klebsiella pneumoniae* BSI organisms (151 positive and 170 negative by the eazyplex^®^ SuperBug CRE assay detection) according to the presence of resistance genesType of β-lactamase in the indicated species (no. of isolates)^a^No. (%) of isolates susceptible to the following antimicrobial agentsCTXCAZFEPETPMEMTZPAKGMCIPSXTTGCCST*E. coli* (214)*bla*~CTX-M~ (77)0 (0.0)5 (6.5)0 (0.0)77 (100)77 (100)53 (68.8)51 (66.2)47 (61)6 (7.8)38 (49.3)----*bla*~CMY~ (5)^b^0 (0.0)0 (0.0)5 (100)5 (100)5 (100)1 (20.0)4 (80.0)3 (60.0)1 (20.0)1 (20.0)----*bla*~KPC~/*bla*~VIM~ (2)000000110122None (130)130 (100)130 (100)130 (100)130 (100)130 (100)114 (87.7)129 (99.2)113 (86.9)95 (73.1)83 (63.8)----*K. pneumoniae* (107)*bla*~CTX-M~ (23)0 (0.0)0 (0.0)0 (0.0)23 (100)23 (100)6 (26.1)17 (73.9)6 (26.1)2 (8.7)3 (13.0)----*bla*~CMY~ (1)^b^1110001111----*bla*~KPC~/*bla*~VIM~ (49)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)12 (24.5)41 (83.7)2 (4.0)9 (18.4)39 (78.6)29 (59.2)None (34)34 (100)34 (100)34 (100)34 (100)34 (100)30 (88.2)34 (100)34 (100)30 (88.2)31 (91.2)----[^2][^3]

Within few hours after BCs were drawn, physicians started empirical antimicrobial therapy in all the 321 patients. The antibiotics most frequently used were piperacillin-tazobactam (24.3%) and fluoroquinolones (23.7%) followed by carba (16.2%) and ESC (8.7%); when combination therapy was used, piperacillin-tazobactam plus amikacin (9.3%) was the most frequent antibiotic regimen. In most cases (85.0%), the physician in charge of the patient made the choice of the empirical treatment, and did not use a predefined protocol. As shown in [Table 2](#T0002){ref-type="table"}, empirical antimicrobial therapy was appropriate in 41.1% (132/321) of BSIs, with 5.9% (3/51) for KPC/VIM BSIs and 30.0% (30/100) for CTX-M BSIs ([Figure 2](#F0002){ref-type="fig"}).Table 2Appropriate empirical or diagnostic-driven antimicrobial treatments stratified by the type of organisms causing bloodstream infections in 321 patientsNo. (%) of appropriate empirical treatmentsNo. (%) of modifications leading to appropriate treatments, according to the results byMALDI BioTyper^TM^ analysis plus eazyplex^®^ SuperBug CRE assayAntimicrobial susceptibility testingOrganisms causing BSIKPC/VIM-producing *E. coli* (n=2)0/2 (0.0)2/2 (100)0/2 (0.0)CTX-M-producing *E. coli* (n=77)22/77 (28.6)48/77 (62.3)7/77 (9.1)CMY-producing *E. coli* (n=5)1/5 (20.0)3/5 (60.0)1/5 (20.0)ESCS-carbaS *E. coli* (n=130)77/130 (59.2)44/130 (33.8)9/130 (6.9)KPC/VIM-producing *K. pneumoniae* (n=49)3/49 (6.1)31/49 (63.3)14/49 (28.6)^a^CTX-M-producing *K. pneumoniae* (n=23)8/23 (34.8)14/23 (60.9)1/23 (4.3)CMY-producing *K. pneumoniae* (n=1)1/1 (100)0/1 (0.0)0/1 (0.0)ESCS-carbaS *K. pneumoniae* (n=34)20/34 (58.8)12/34 (35.3)2/34 (5.9)Total organisms (n=321)132/321 (41.1)154/321 (48.0)34/321 (10.6)^a^[^4] Figure 2Appropriateness of antimicrobial treatments in subgroups defined by the presence of the indicated resistance determinants in 321 patients with *Ec* or *Kp* bloodstream infections. Empirical or targeted antimicrobial therapy was the administration of antibiotics before and after the eazyplex^®^ SuperBug CRE assay results were available, respectively. Definitive antimicrobial therapy was the administration of antibiotics after the antimicrobial susceptibility testing results were available. Overall, antimicrobial therapy was appropriate for any antibiotic with known susceptibility by microbiology report.

After notification of results from both the MALDI BioTyper^TM^ analysis and eazyplex^®^ SuperBug CRE assay, the IDCT specialists recommended a modification of the empirical antimicrobial therapy ([Table 2](#T0002){ref-type="table"}). These actions increased the proportion of appropriate antimicrobial therapy to 89.1% (286/321), with 92.0% (92/100) for CTX-M BSIs and 70.6% (36/51) for KPC/VIM BSIs ([Figure 2](#F0002){ref-type="fig"}). The remaining 35 patients, 15 and 8 of whom were infected by carbapenemase- or CTX-M-producing *Ec* or *Kp* organisms, respectively, received antimicrobial treatments that were different from the previous empirical treatments, but the selected drug(s) were still inactive (as later documented by AST on the relative isolates). The drugs were meropenem plus colistin in 15 patients (all infected with colistin-resistant KPC-producing *Kp* isolates), piperacillin-tazobactam in 15 patients (8 with non-CTX M ESBL-producing isolates, 6 with ESCS-CarbaS isolates, and 1 with CMY-producing isolates), and fluoroquinolones in 5 patients.

Following release of AST results, antimicrobial therapies were further modified in the 35 aforementioned patients ([Table 2](#T0002){ref-type="table"}), leading to a proportion of appropriate treatments up to 99.7% (320/321 patients) ([Figure 2](#F0002){ref-type="fig"}). One patient never received effective therapy, as the infecting *Kp* isolate was resistant to all the antibiotics tested ([Table 1](#T0001){ref-type="table"}).

Discussion {#S0004}
==========

To the best of our knowledge, this study is the first large hospital-based report that has evaluated the effects of the rapid detection of *Ec* and *Kp* isolates producing *bla*~CTX-M~ or *bla*~KPC~ or *bla*~VIM~ on the timing of appropriate antimicrobial therapy. Several recent studies have performed similar evaluations,[@CIT0011],[@CIT0012],[@CIT0023],[@CIT0024] but all have involved a small number of patients with CTX-M- and carbaR-BSI, and none of these studies used the eazyplex^®^ SuperBug CRE assay as a rapid resistance detection method. Here, integrating this assay with MALDI BioTyper^TM^ analysis, our diagnostic algorithm allowed the successful identification of all *Ec* and *Kp* producing *bla*~CTX-M~, and/or *bla*~KPC~ and/or *bla*~VIM~, and, more importantly, the antimicrobial streamlining in the course of BSI. Therefore, this study has some strengths. First, the results by the proposed laboratory workflow are obtainable in a mean time of 18 h, which may help clinicians to provide more therapy that is effective during the early period of clinical illness and may facilitate rapid decisions regarding isolating patients to prevent transmission. Second, the procedure underlying this workflow is simple and easy to perform and requires minimal training. Third, rapidly detecting a specific type of carbapenemase is particularly important because of the introduction of new antibiotics potentially active against certain carbapenemases into the clinical practice. In this context, our workflow is undoubtedly a positive contribution to infection control/effective treatment of patients.

Prior to the implementation of the rapid BC strategy in our hospital, we noted significant delays in initiating effective antimicrobial therapy.[@CIT0002],[@CIT0025] Conversely, based on the strategy shown here, the IDCT specialists switched 64.7% of patients with KPC/VIM BSI and 62.0% of patients with CTX-M BSI from inappropriate empirical antimicrobial regimen to effective coverage within a mean time of 20 h. In the remaining 23 patients on inappropriate empirical therapy, 15 of whom were infected by KPC producers and eight by CTX-M producers, the original regimen was discontinued, but each patient was treated with a drug against which his/her isolate had displayed resistance in AST testing. All 15 patients with KPC BSI that maintained an ineffective coverage received a colistin-based regimen. A problem of considerable importance is the increasing rate of colistin-resistance among KPC-producing *Kp* isolates because of its shortage of therapeutic options in patients with BSIs.[@CIT0026] There is an endemic widespread of such isolates in Italian healthcare facilities,[@CIT0027],[@CIT0028] and it was approximately 40% in our hospital.

The ineffective drug was piperacillin-tazobactam in all but one patients infected by CTX-M producers. Carbapenems seem to be a suitable option for treating severe infections due to those organisms; however, their increased use exerts selection pressure for carbapenem resistance. Therefore, experts have suggested carbapenem-sparing antibiotic regimens, particularly in settings such as ours where carbapenem-resistant isolates are common. Although there is emerging evidence that piperacillin-tazobactam may be a good choice for treating ESBL BSIs, its role is still controversial, particularly for BSIs from non-urinary sources.[@CIT0029]--[@CIT0033] Additionally, the susceptibility of ESBL producers to piperacillin-tazobactam is less predictable than their susceptibility to carbapenems.[@CIT0002],[@CIT0004],[@CIT0020] Among our isolates, rates of resistance ranged from 31.2% of CTX-M-producing *Ec* isolates to 73.9% of CTX-M-producing *Kp* isolates. Therefore, physicians need to base their decisions regarding the empirical use of this antibiotic, until susceptibility results are available, on a sound knowledge of the local susceptibility patterns and the patient's clinical condition.

This study has some well-acknowledged limitations. First, as we conducted our analysis in a single center, the results are not necessarily applicable to other hospitals, particularly those with very low rates of *Enterobacteriaceae* infections caused by CTX-M and/or carbapenemase producers. Second, the eazyplex^®^ SuperBug CRE assay's main weakness is its inability to identify ESBLs other than CTX-M, plasmidic AmpC, and some OXA-48-like enzymes, which are found among currently spreading MDR members of *Enterobacteriaceae*.[@CIT0004],[@CIT0028] Therefore, without the ability to detect these resistance determinants, the assay would miss a significant proportion of resistant isolates if implemented in settings where isolates harboring those genes occur.

Conclusion {#S0005}
==========

Our combined use of the MALDI BioTyper^TM^ analysis and eazyplex^®^ SuperBug CRE assay can be a reliable, timesaving alternative to the conventional laboratory diagnosis of BSIs caused by *Ec* or *Kp* organisms with MDR determinants (ie, CTX-M ESBLs and carbapenemases). Importantly, this rapid diagnosis can enable physicians to begin appropriate antimicrobial therapy precociously. However, the applicability of our diagnostic workflow does depend on the conditions dictated by aforementioned limitations, as well as further larger studies are necessary to validate and confirm the present findings.
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[^2]: **Notes:** Colistin and tigecycline susceptibility results were available only for carbapenem-resistant isolates. We did not calculate percentages in cases with less than five isolates. ^a^We identified the extended-spectrum β-lactamase (ESBL), plasmidic AmpC β-lactamase, and carbapenemase genes by standard PCR sequencing analysis. Specifically, *E. coli* isolates harbored *bla*~CTX-M-15~ (n=55), *bla*~CTX-M-14~ (n=9), *bla*~CTX-M-27~ (n=13), *bla*~CMY-2~ (n=5), *bla*~KPC-3~ (n=1), and *bla*~VIM-1~ (n=1); *K. pneumoniae* isolates harbored *bla*~CTX-M-15~ (n=23), *bla*~CMY-2~ (n=1), *bla*~KPC-2~ (n=2), *bla*~CTX-M-15~+ *bla*~KPC-3~ (n=4), *bla*~KPC-3~ (n=41), and *bla*~KPC-3~+ *bla*~VIM-1~ (n=2). None refers to the isolates not harboring such genes. ^b^Six isolates harboring *bla*~CMY~ genes had a negative result with the eazyplex^®^ SuperBug CRE assay.

[^3]: **Abbreviations:** CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; MEM, meropenem; TZP, piperacillin-tazobactam; AK, amikacin; GM, gentamicin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; CST, colistin.

[^4]: **Notes:** ^a^The treatment was not appropriate in 1 (0.3%) of 321 BSIs because the infecting KPC/VIM-producing *K. pneumoniae* organism had an AST-determined pandrug resistance phenotype.

    **Abbreviations:** CRE, carbapenemase-resistant *Enterobacteriaceae*; BSI, bloodstream infection; ESCS-carbaS, extended-spectrum cephalosporin susceptible-carbapenem susceptible.
